REG - Ergomed plc - Exercise of Options

ErgomedAnnouncement

17/01/2020 07:05

RNS Number : 0964A
Ergomed plc
17 January 2020
 


 PRESS RELEASE
 
Exercise of Share Options and Total Voting Rights
Guildford, UK - 17 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 450,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares"). 
Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 20 January 2020.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.
Following Admission, the total number of ordinary shares with voting rights in issue will be 47,757,177. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.  As well as the New Ordinary Shares, this figure includes 20,888 ordinary shares issued since 31 December 2019 and admitted to AIM pursuant to the Company's block listing in respect of the Ergomed plc Long Term Incentive Plan.
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser

















 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBFMBTMTTBTTM